Evaluation of Platelet Rich Plasma for Treatment of Female Pattern Hair Loss: A Placebo-Controlled Case Study

Ruri D. Pamela
{"title":"Evaluation of Platelet Rich Plasma for Treatment of Female Pattern Hair Loss: A Placebo-Controlled Case Study","authors":"Ruri D. Pamela","doi":"10.46889/jdr.2022.3303","DOIUrl":null,"url":null,"abstract":"Background: Platelet Rich Plasma (PRP) is an autologous concentration of human platelets contained in a small volume of plasma, has been proposed as a potential adjuvant therapy to Female Pattern Hair Loss (FPHL). Despite the widespread use of PRP in numerous fields of medicine, there have been few studies that investigated the clinical efficacy of PRP in FPHL.\n\nMethods: Fourteen female patients, age ranged from 20-45 years, diagnosed with female pattern hair loss were enrolled in this single-blinded randomized placebo-controlled study. Fourteen patients were divided randomly into two groups: Group 1 were injected with PRP using insulin syringe and group 2 were injected with normal saline as placebo. All patients were followed at 3 and 6 months after the last treatment sessions. Of the total subjects enrolled, on ten subjects completed the study. In total, 7 (70%) individuals received PRP and 3 (30%) received placebo. During all the treatment sessions, there were no severe adverse events reported. The study yielded investigator, subject and photographic assessments.\n\nResults: On the basis of the independent-blinded investigator assessment of change in the patient’s scalp hair growth from baseline, treatment in PRP group demonstrated as scale 1 improvement in 5 subjects (26-50%) and scale 2 improvement in 2 subjects (51-75%) at the final visit as compared to baseline (Fig. 1,2). In contrast, in the placebo group were rated as scale 0 improvement (0-25%).\n\nConclusion: PRP injection for FPHL is a simple, cost-effective and feasible treatment option with good safety profile. However more randomized and multicentric trials with a large number of patients will be required to prove the validity of these results, to obtain these answers and to get more robust statistical results.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical & experimental dermatology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46889/jdr.2022.3303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Platelet Rich Plasma (PRP) is an autologous concentration of human platelets contained in a small volume of plasma, has been proposed as a potential adjuvant therapy to Female Pattern Hair Loss (FPHL). Despite the widespread use of PRP in numerous fields of medicine, there have been few studies that investigated the clinical efficacy of PRP in FPHL. Methods: Fourteen female patients, age ranged from 20-45 years, diagnosed with female pattern hair loss were enrolled in this single-blinded randomized placebo-controlled study. Fourteen patients were divided randomly into two groups: Group 1 were injected with PRP using insulin syringe and group 2 were injected with normal saline as placebo. All patients were followed at 3 and 6 months after the last treatment sessions. Of the total subjects enrolled, on ten subjects completed the study. In total, 7 (70%) individuals received PRP and 3 (30%) received placebo. During all the treatment sessions, there were no severe adverse events reported. The study yielded investigator, subject and photographic assessments. Results: On the basis of the independent-blinded investigator assessment of change in the patient’s scalp hair growth from baseline, treatment in PRP group demonstrated as scale 1 improvement in 5 subjects (26-50%) and scale 2 improvement in 2 subjects (51-75%) at the final visit as compared to baseline (Fig. 1,2). In contrast, in the placebo group were rated as scale 0 improvement (0-25%). Conclusion: PRP injection for FPHL is a simple, cost-effective and feasible treatment option with good safety profile. However more randomized and multicentric trials with a large number of patients will be required to prove the validity of these results, to obtain these answers and to get more robust statistical results.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评价富血小板血浆治疗女性型脱发:一项安慰剂对照病例研究
背景:富血小板血浆(PRP)是一种包含在小体积血浆中的自体浓度的人血小板,已被提出作为一种潜在的辅助治疗女性型脱发(FPHL)。尽管PRP在许多医学领域被广泛使用,但很少有研究调查PRP在FPHL中的临床疗效。方法:14例女性脱发患者,年龄在20-45岁之间,入选单盲随机安慰剂对照研究。14例患者随机分为两组:第一组使用胰岛素注射器注射PRP,第二组使用生理盐水作为安慰剂注射。在最后一次治疗后3个月和6个月对所有患者进行随访。在所有入组的受试者中,有10名受试者完成了研究。总共有7人(70%)接受PRP治疗,3人(30%)接受安慰剂治疗。在所有的治疗过程中,没有严重的不良事件报告。该研究产生了研究者、受试者和照片评估。结果:根据独立盲法研究者对患者头皮毛发生长变化的基线评估,与基线相比,PRP组在最后一次就诊时,有5名受试者(26-50%)获得了1级改善,2名受试者(51-75%)获得了2级改善(图1,2)。相比之下,安慰剂组被评为0级改善(0-25%)。结论:注射PRP治疗FPHL是一种简单、经济、可行的治疗方法,安全性好。然而,需要更多的随机和多中心的大量患者试验来证明这些结果的有效性,以获得这些答案,并获得更稳健的统计结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Observed Causal Relationship Between Eczema and Inflammatory Bowel Diseases Transient Eosinophilic Nodulomatosis: A Report of Two Cases ORF Nodule Complicated by Erythema Multiforme: About 2 Cases Erythema Nodosum Leprosum and Thalidomide: How Effective? Autoimmune Diseases a Late Complication of Toxic Epidermal Necrolysis: A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1